In preclinical experiments, the combination of BEZ235 and enzalutamide (an androgen-receptor antagonist) demonstrated near-complete tumor regression in a PTEN-deficient murine model and in human prostate cancer xenografts.5 A phase Ib proof-of-concept trial of BEZ235 or buparlisib in combination with abiraterone acetate is currently enrolling patients with CRPC after progression on abiraterone acetate (NCT01634061). This evidence concerns the gene PTEN and Familial prostate cancer.